XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events
9 Months Ended
Sep. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events

(10) Subsequent Events

Subsequent to September 30, 2017, the Company entered into an agreement with Aeolus pursuant to which the Company acquired Aeolus’ minority membership interest in CPEC.  The transaction effectively buys-out Aeolus’ royalty interest thereby reducing or eliminating certain milestone and royalty obligations that could be payable by the Company, if Gencaro receives regulatory approval and is commercialized.  As a result of this transaction, the Company, together with Endo Pharmaceuticals, Inc., indirectly have the rights to the Gencaro program, as discussed in Note 6 above.  The acquisition cost of this interest will not have a significant impact on the Company’s annual financial statements.